調查範圍
- 調查範圍
摘要
- 摘要
γ 照相機的市場分析
- 市場概要–市場傾向
- 市場概要–技術傾向
- 臨床治療部門分析
- 依地區不同之分析
- 癌症研究的發達
- GE–Amersham收購
- 競爭展望–組織與方法論
- 競爭展望–市場佔有
參考統計資料
- 參考統計資料
Frost ＆ Sullivan 調查能力
- 團隊
- 諮詢能力

Nuclear gamma cameras are a very important imaging modality for molecular imaging and their strength lies mainly in the large global installed base and the availability of longer half-life radioisotopes such as Technetium-99m (with a half-life of 6 hours). However, robust market growth is expected to depend on the development of novel diagnostic and therapeutic imaging agents. In the face of increasing competition for budget/resources from positron emission tomography (PET), new imaging agents can create fresh clinical applications for gamma cameras and help expand the market.

This Frost & Sullivan strategic analysis service explores the nuclear gamma camera's key competitive advantage with respect to PET scanners and looks at two developments that may potentially change the industry landscape: new diagnostic/therapeutic agents successfully passing clinical trials, and the upcoming launch of hybrid single photon emission computed tomography (SPECT) imaging systems. The study covers general imaging and cardiology applications using single-, double-, and triple-head SPECT/CT.

Developments in Radio-immunotherapy Drive Market Growth

Currently, nuclear cardiology is the key driver for growth in the U.S. nuclear gamma camera markets with two imaging agents for myocardial perfusion imaging – Cardiolite and Myoview – holding the major share in the SPECT imaging agents market. However, some very promising radio-immunotherapeutic drugs in the clinical pipeline may open gamma cameras to the cancer treatment market. "In the oncology arena, two approved diagnostic and therapeutic agents targeted for non-Hodgkin's Lymphoma – Zevalin and Bexxar – have the potential of achieving widespread clinical adoption in the coming years," says the analyst of the research.

Hybrid SPECT/CT Imaging Systems Present New Growth Opportunities

Revenues from the global gamma camera market reached $638.0 million in 2003. The introduction and clinical acceptance of hybrid SPECT/CT systems such as GE Medical Systems?f Infinia Hawkeye are expected to further accelerate growth. These hybrid imaging systems complement functional imaging of SPECT with anatomical imaging of CT. As a result, the performance of both new and approved imaging agents such as ProstaScint can be significantly improved.

SAS REPORT
- Research Scope
  - Research Scope
- Executive Summary
  - Executive Summary
- Gamma Camera Market Analysis
  - Market Overview - Market Trends
  - Market Overview - Technology Trends
  - Clinical Segment Analysis
  - Geographic Analysis
  - Developments in Oncology
  - GE-Amersham Acquisition
  - Competitive Landscape - Structure and Methodology
  - Competitive Landscape - Market Share
- Decision Support Data
  - Decision Support Data
- Frost & Sullivan Awards
  - Frost & Sullivan Awards
- Frost & Sullivan Research Capabilities
  - Our Team
  - Consulting Capabilities